Departamento de Bioquimica, Facultad de Medicina, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico.
Virology. 2010 Sep 15;405(1):31-40. doi: 10.1016/j.virol.2010.05.011. Epub 2010 Jun 15.
We have developed microarrays with all eight proteins encoded by 13 different human papillomavirus types associated with anogenital cancer (HPV-16, -18, -31, -33, -35, -45, and -53), genital warts (HPV-6 and -11), or skin lesions (HPV-1, -2, -4, and -5). We analyzed the seroprevalence of antibodies in 546 patients, which had either cervical carcinomas, or precursor lesions, or which were asymptomatic. All patient groups contained sera ranging from high reactivity against multiple HPV proteins to low or no reactivity. Computational analyses showed the E7 proteins of carcinogenic HPV types as significantly more reactive in cancer patients compared to asymptomatic individuals and discriminating between cancer and HSIL or LSIL patients. Antibodies against E4 and E5 had the highest seroprevalence but did not exhibit differential reactivity relative to pathology. Our study introduces a new approach to future evaluation of the overall antigenicity of HPV proteins and cross-reaction between homologous proteins.
我们开发了微阵列,其中包含与肛门生殖器癌(HPV-16、-18、-31、-33、-35、-45 和 -53)、生殖器疣(HPV-6 和 -11)或皮肤病变(HPV-1、-2、-4 和 -5)相关的 13 种不同人类乳头瘤病毒类型所编码的所有 8 种蛋白质。我们分析了 546 名患者的血清抗体流行率,这些患者要么患有宫颈癌或前体病变,要么无症状。所有患者组均包含从针对多种 HPV 蛋白的高反应性到低反应性或无反应性的血清。计算分析显示,致癌 HPV 类型的 E7 蛋白在癌症患者中的反应性明显高于无症状个体,并能区分癌症与 HSIL 或 LSIL 患者。针对 E4 和 E5 的抗体具有最高的血清流行率,但相对于病理学没有表现出不同的反应性。我们的研究介绍了一种新方法,用于未来评估 HPV 蛋白的整体抗原性和同源蛋白之间的交叉反应性。